340B Purchases Surge Past $100 Billion

Commentary: Change would endanger SC's vulnerable, uninsured to hike drug company profits

Changes to federal law would raise profits for drug companies, PBMs by reducing coverage for vulnerable and uninsured at nonprofit health centers.

Dr. Oz just fired a $4.5 billion shot at big hospital hypocrisy

The 340B drug discount program grew to an eye-popping $100 billion in drug sales in 2025, making it the largest government program most people have never heard of. Enacted under the Public Health Service Act to require drug manufacturers to provide outpatient drugs at steep discounts to safety-net hospitals serving low-income patients, 340B has metastasized into a massive revenue engine for big nonprofit hospital systems. They use it to pocket b…

Big Pharma Drains Rural Lifelines

America’s rural health care crisis is not primarily a partisan failure of Democrats or Republicans; it is the predictable outcome of a financing system that lets drug manufacturers and other medical monopolies extract revenue from fragile hospitals and pharmacies faster than public programs and small communities can replace it. Key Points Rural hospitals and clinics...

Democrats Will Blame the GOP for Rural Healthcare. Big Pharma Is the One Killing It.

Big Pharma, not GOP, threatens rural healthcare by undermining the 340B drug discount program.

340B Purchases Surge Past $100 Billion

On July 15, the Health Resources & Services Administration (HRSA) released the 2025 update to its annual report on 340B covered entity purchases. Drug purchases at discounted 340B prices reached a record of $100 billion in 2025, representing a 23% increase from 2024. This data allows stakeholders to better understand the size of the 340B program and its use by different covered entity types. The data reported by HRSA is from the Prime Vendor Pro…